~~WE~~ CLAIMS:

1. A chromatographic process for purification of insulin analogue, atosiban or eptifibatide from a mixture having at least one related impurity, at a pH ranging from about 2.5 to about 8.5, said process comprising steps of:

a) packing RP-HPLC column with silica (C_4-C_{18}) based resin, equilibrated with about 5% to about 85 % organic modifier;

b) loading the insulin analogue, atosiban or eptifibatide mixture on the column at a flow rate of about 180 cm/hr to about 360 cm/hr;

c) washing the column with an ion pairing agent having concentration ranging from about 0.05% to about 1% in combination with the organic modifier having concentration ranging from about 5% to about 85%, at pH ranging from about 2.5 to about 8.5 and;

d) performing a linear gradient of about 10% to about 70% for eluting the purified insulin analogue, atosiban or eptifibatide from the column.

2. The process as claimed in claim 1, wherein the insulin analogue is selected from a group comprising Aspart, Lispro and Glargine or any combination thereof.

3. The process as claimed in claim 1, wherein the silica resin is preferably C_8.

4. The process as claimed in claim 1 wherein, the resin has a particle size ranging from about 5μ to about 40μ, preferably, from about 7μ to about 20μ, and most preferably from about 10μ to about 13μ.

5. The process as claimed in claim 1, wherein the resin bead has a pore size ranging from about 50Å to about 2000Å, preferably from about 100Å to about 500Å, and most preferably 120Å.

6. The process as claimed in claim 1, wherein the ion pairing agent is selected from a group comprising Hexane sulfonic acid, Trifluoro acetic acid, Pentafluoro propanoic acid, Triethyl amine and Heptafluorobutyric acid.

7. The process as claimed in claim 1, wherein the organic modifier is selected from a group comprising Acetonitrile, Ethanol, Methanol and Isopropyl alcohol.

8. The process as claimed in claims 1 to 7, wherein purity of the insulin analogue, atosiban or eptifibatide is ranging from about 90% to about 100%, preferably at least 99%.

~~9. An Insulin analogue, atosiban, eptifibatide obtained by a process as claimed in claims 1 to 8 with purity ranging from about 90% to about 100%.~~

~~10. Purified Aspart purified with a purity of atleast 98%.~~

~~11. Purified Glargine purified with a purity of atleast 99%.~~

~~12. Purified Lispro purified with a purity of atleast 97%.~~

~~13. Purified Atosiban purified with a purity of atleast 99.14%.~~

~~14. Purified Eptifibatide purified with a purity of atleast 94%.~~